OBJECTIVE： To discuss the solution of therapeutic contradictions of bleeding and hemostasis in pulmonary embolism patients receiving warfarin anticoagulation. METHODS： The risk evaluation and dissolution of bleeding and embolism induced by warfarin anticoagulation were summarized by analyzing therapeutic duration of INR abnormal elevation in a pulmonary embolism patient receiving warfarin anticoagulation. Case analysis was based on foreign and domestic guideline and information. RESULTS： Referring to INR value， based on HAS-BLE， Caprini scale， China Expert Consensus on Anticoagulant Therapy of Warfarin， China Expert Suggestions on Prevention of Venous Thrombosis in Internal Inpatients and Guidelines of Prevention of VTE in Nonsurgical Patients of American College of Chest Physicians， clinical pharmacists and physicians adjusted the dose of Warfarin tablet timely. The patient was recovered after symptomatic treatment of anticoagulation， relieving cough and asthma， reducing phlegm， etc.， and then disagreed from hospital with drugs. CONCLUSIONS： The risk of bleeding and embolism for this type patients can be evaluated and resolved on the basis of HAS-BLED， Caprini scale and relevant guidelines. At present， there still are some problems as deficient evaluation method， lack of large-scale high-level evidence and quantitative study. It is needed to carry out multiple center clinical study and drug interaction quantitative study actively， and develop suitable risk evaluation method so as to provide high-quality and valuable decision-making evidence.